HUP0302044A2 - Egy CB1 receptor antagonista és sibutramin kombinációja, ezt tartalmazó gyógyászati készítmények és alkalmazásuk elhízás kezelésére - Google Patents
Egy CB1 receptor antagonista és sibutramin kombinációja, ezt tartalmazó gyógyászati készítmények és alkalmazásuk elhízás kezeléséreInfo
- Publication number
- HUP0302044A2 HUP0302044A2 HU0302044A HUP0302044A HUP0302044A2 HU P0302044 A2 HUP0302044 A2 HU P0302044A2 HU 0302044 A HU0302044 A HU 0302044A HU P0302044 A HUP0302044 A HU P0302044A HU P0302044 A2 HUP0302044 A2 HU P0302044A2
- Authority
- HU
- Hungary
- Prior art keywords
- receptor antagonist
- sibutramin
- association
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 abstract 1
- 229960004425 sibutramine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány egy (I) általános képletű CB1 receptor antagonista éssibutramin, annak hidrátja vagy gyógyászatilag elfogadható sójakombinációjára, az ezeket tartalmazó gyógyászati készítményekre éselhízás kezelésére történő alkalmazásukra vonatkozik. Az (I) általánosképletben R jelentése (A) vagy (B) általános képletű csoport - ahol R1jelentése metil- vagy etilcsoport R2 jelentése fenil-, naftil- vagyindenilcsoport közül választott aromás csoport, amelyek adott esetbenszubsztituáltak lehetnek R3 és R4 jelentése azonos vagy különböző ésjelentése fenil- naftil-, vagy indenilcsoport közül választott aromáscsoportok lehetnek, amelyek adott esetben szubsztituáltak. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0012646A FR2814678B1 (fr) | 2000-10-04 | 2000-10-04 | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
PCT/FR2001/003022 WO2002028346A2 (fr) | 2000-10-04 | 2001-10-01 | Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0302044A2 true HUP0302044A2 (hu) | 2003-11-28 |
HUP0302044A3 HUP0302044A3 (en) | 2005-05-30 |
Family
ID=8854974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0302044A HUP0302044A3 (en) | 2000-10-04 | 2001-10-01 | Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1328269B2 (hu) |
JP (1) | JP4221221B2 (hu) |
KR (1) | KR20030036885A (hu) |
CN (1) | CN100409845C (hu) |
AT (1) | ATE267595T1 (hu) |
AU (2) | AU2001293936B2 (hu) |
BG (1) | BG107739A (hu) |
BR (1) | BR0114410A (hu) |
CA (1) | CA2424934A1 (hu) |
DE (1) | DE60103556T3 (hu) |
DK (1) | DK1328269T5 (hu) |
EA (1) | EA005924B1 (hu) |
EE (1) | EE200300121A (hu) |
ES (1) | ES2217191T5 (hu) |
FR (1) | FR2814678B1 (hu) |
HR (1) | HRP20030249A2 (hu) |
HU (1) | HUP0302044A3 (hu) |
IL (1) | IL155236A0 (hu) |
MX (1) | MXPA03002845A (hu) |
NO (1) | NO20031521L (hu) |
NZ (1) | NZ524904A (hu) |
PL (1) | PL362833A1 (hu) |
PT (1) | PT1328269E (hu) |
SI (1) | SI1328269T2 (hu) |
SK (1) | SK4032003A3 (hu) |
TR (1) | TR200401264T4 (hu) |
WO (1) | WO2002028346A2 (hu) |
YU (1) | YU26103A (hu) |
ZA (1) | ZA200303015B (hu) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2833842B1 (fr) * | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
CA2479744A1 (en) | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
JP4459629B2 (ja) | 2002-04-12 | 2010-04-28 | メルク エンド カムパニー インコーポレーテッド | 二環式アミド |
WO2004013120A1 (en) | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
ES2334565T3 (es) | 2003-01-02 | 2010-03-12 | Hoffmann La Roche | Agonistas inversos del receptor cb 1. |
PL378244A1 (pl) | 2003-01-02 | 2006-03-20 | F. Hoffmann-La Roche Ag | Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1 |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
JP3939744B2 (ja) | 2003-06-11 | 2007-07-04 | メルク エンド カムパニー インコーポレーテッド | 置換3−アルキルおよび3−アルケニルアゼチジン誘導体 |
BRPI0411699A (pt) | 2003-06-20 | 2006-08-29 | Hoffmannn La Roche Ag F | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos |
EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
RU2006110545A (ru) * | 2003-09-02 | 2007-10-10 | Зольвай Фармасьютикалз Гмбх (De) | Новое медицинское применение избирательных антагонистов св1-рецептора |
FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
WO2005049615A1 (en) * | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists |
KR100773650B1 (ko) | 2003-12-08 | 2007-11-05 | 에프. 호프만-라 로슈 아게 | 신규한 싸이아졸 유도체 |
KR100843023B1 (ko) | 2004-01-28 | 2008-07-01 | 에프. 호프만-라 로슈 아게 | 스피로-5환 화합물 |
KR100870346B1 (ko) | 2004-05-10 | 2008-11-25 | 에프. 호프만-라 로슈 아게 | 비만 치료용 피롤 또는 이미다졸 아마이드 |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
WO2006039334A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
FR2876689B1 (fr) * | 2004-10-14 | 2008-02-22 | Aventis Pharma Sa | Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide |
WO2006045799A2 (en) | 2004-10-25 | 2006-05-04 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
BRPI0517369A (pt) | 2004-10-27 | 2008-10-07 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização |
RU2391337C2 (ru) | 2004-11-09 | 2010-06-10 | Ф.Хоффманн-Ля Рош Аг | Производные дибензосуберона |
CA2602787C (en) | 2005-04-06 | 2013-12-24 | F. Hoffmann-La Roche Ag | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
US20090264470A1 (en) * | 2006-02-21 | 2009-10-22 | Bennett Teresa A | CB1 Antagonists and Inverse Agonists |
WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
WO2008038143A2 (en) * | 2006-06-22 | 2008-04-03 | Medichem, S.A. | Novel solid forms of rimonabant and synthetic processes for their preparation |
EP2057144A4 (en) * | 2006-09-01 | 2010-06-02 | Hetero Drugs Ltd | NEW POLYMORPHIC FROM RIMONABANT |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
JP5030114B2 (ja) * | 2006-09-25 | 2012-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体をモジュレートする化合物 |
DE102007002260A1 (de) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
EP1953144A1 (en) * | 2007-01-30 | 2008-08-06 | Sandoz AG | Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide |
WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
CA2709863A1 (fr) * | 2007-12-18 | 2009-09-03 | Sanofi-Aventis | Derives d'azetidines, leur preparation et leur application en therapeutique |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
BRPI0902481B8 (pt) | 2009-07-31 | 2021-05-25 | Soc Beneficente De Senhoras Hospital Sirio Libanes | composição farmacêutica compreendendo hemopressina e seu uso. |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE61928B1 (en) † | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
JPH04360167A (ja) * | 1991-06-06 | 1992-12-14 | Mitsubishi Kasei Corp | 近接帯電装置 |
FR2713225B1 (fr) † | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
JPH07209959A (ja) * | 1994-01-24 | 1995-08-11 | Ricoh Co Ltd | 帯電装置 |
US5596106A (en) † | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
US6482927B1 (en) * | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
GB9619961D0 (en) * | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
WO1998018481A1 (en) † | 1996-10-31 | 1998-05-07 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
FR2758723B1 (fr) † | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
WO1999006110A1 (en) * | 1997-07-29 | 1999-02-11 | Silicon Genesis Corporation | Cluster tool method and apparatus using plasma immersion ion implantation |
EP0920864A1 (en) † | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
KR100652994B1 (ko) † | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
-
2000
- 2000-10-04 FR FR0012646A patent/FR2814678B1/fr not_active Expired - Fee Related
-
2001
- 2001-10-01 JP JP2002531972A patent/JP4221221B2/ja not_active Expired - Fee Related
- 2001-10-01 KR KR10-2003-7004772A patent/KR20030036885A/ko not_active Application Discontinuation
- 2001-10-01 HU HU0302044A patent/HUP0302044A3/hu unknown
- 2001-10-01 AT AT01974413T patent/ATE267595T1/de not_active IP Right Cessation
- 2001-10-01 DK DK01974413T patent/DK1328269T5/da active
- 2001-10-01 WO PCT/FR2001/003022 patent/WO2002028346A2/fr active IP Right Grant
- 2001-10-01 PT PT01974413T patent/PT1328269E/pt unknown
- 2001-10-01 MX MXPA03002845A patent/MXPA03002845A/es active IP Right Grant
- 2001-10-01 IL IL15523601A patent/IL155236A0/xx unknown
- 2001-10-01 SK SK403-2003A patent/SK4032003A3/sk not_active Application Discontinuation
- 2001-10-01 CA CA002424934A patent/CA2424934A1/fr not_active Abandoned
- 2001-10-01 AU AU2001293936A patent/AU2001293936B2/en not_active Ceased
- 2001-10-01 TR TR2004/01264T patent/TR200401264T4/xx unknown
- 2001-10-01 AU AU9393601A patent/AU9393601A/xx active Pending
- 2001-10-01 SI SI200130139T patent/SI1328269T2/sl unknown
- 2001-10-01 DE DE60103556T patent/DE60103556T3/de not_active Expired - Lifetime
- 2001-10-01 PL PL01362833A patent/PL362833A1/xx not_active Application Discontinuation
- 2001-10-01 BR BR0114410-3A patent/BR0114410A/pt not_active IP Right Cessation
- 2001-10-01 EP EP01974413A patent/EP1328269B2/fr not_active Expired - Lifetime
- 2001-10-01 ES ES01974413T patent/ES2217191T5/es not_active Expired - Lifetime
- 2001-10-01 YU YU26103A patent/YU26103A/sh unknown
- 2001-10-01 EA EA200300441A patent/EA005924B1/ru not_active IP Right Cessation
- 2001-10-01 CN CNB018182682A patent/CN100409845C/zh not_active Expired - Fee Related
- 2001-10-01 EE EEP200300121A patent/EE200300121A/xx unknown
- 2001-10-01 NZ NZ524904A patent/NZ524904A/en unknown
-
2003
- 2003-04-02 HR HR20030249A patent/HRP20030249A2/hr not_active Application Discontinuation
- 2003-04-03 NO NO20031521A patent/NO20031521L/no not_active Application Discontinuation
- 2003-04-16 ZA ZA200303015A patent/ZA200303015B/en unknown
- 2003-04-17 BG BG107739A patent/BG107739A/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302044A2 (hu) | Egy CB1 receptor antagonista és sibutramin kombinációja, ezt tartalmazó gyógyászati készítmények és alkalmazásuk elhízás kezelésére | |
HUP0300340A2 (hu) | c-JUN N-terminális kinázok (JNK) és más protein kinázok inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
PT1263725E (pt) | Novos compostos | |
TR200200778T2 (tr) | Pirazol türevleri. | |
IS6658A (is) | Ný efnasambönd | |
ATE390421T1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
ATE316083T1 (de) | Adamantanderivate | |
DE602004024375D1 (de) | Carboxamidderivate | |
EE05400B1 (et) | Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks | |
ATE250590T1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
WO2002085925A3 (en) | Melanocortin receptor ligands | |
BR9915132A (pt) | Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica. | |
SI1506185T1 (sl) | Spojine in njihova uporaba kot inhibitorji 5-HT | |
IL161582A0 (en) | Use of oxindole hydrazide derivatives for the preparation of pharmaceutical compositions, certain such new derivatives and their preparation | |
ATE386725T1 (de) | Heterocyclylverbindungen | |
HUP0003851A2 (hu) | Gyógyszerkészítmény glomerulopathia kezelésére vagy megelőzésére | |
DK1747220T3 (da) | Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon | |
HUP9700005A2 (hu) | 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
MY133512A (en) | Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | |
DK1165544T3 (da) | Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase | |
HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
HUP0201878A2 (hu) | Sibutramint és orlistatot tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |